(en) Toyn, « What lessons can be learned from failed Alzheimer's disease trials? », Expert Rev. Clin. Pharmacol, vol. 8, no 3, , p. 267-9. (PMID25860157, DOI10.1586/17512433.2015.1034690)
Sevigny J., Chiao P., Bussière T. et Weinreb P.H., « The antibody aducanumab reduces Aβ plaques in Alzheimer's disease », Nature, vol. 537, no 7618, , p. 50-6. (PMID27582220, DOI10.1038/nature19323)
(en) Joseph W. Arndt, Fang Qian, Benjamin A. Smith et Chao Quan, « Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β », Scientific Reports, vol. 8, no 1, , p. 6412 (ISSN2045-2322, DOI10.1038/s41598-018-24501-0, lire en ligne, consulté le )
(en) Eric Karran, Marc Mercken et Bart De Strooper, « The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics », Nature Reviews Drug Discovery, vol. 10, no 9, , p. 698–712 (ISSN1474-1784, DOI10.1038/nrd3505, lire en ligne, consulté le )
(en) Joseph W. Arndt, Fang Qian, Benjamin A. Smith et Chao Quan, « Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β », Scientific Reports, vol. 8, no 1, , p. 6412 (ISSN2045-2322, DOI10.1038/s41598-018-24501-0, lire en ligne, consulté le )
(en) Eric Karran, Marc Mercken et Bart De Strooper, « The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics », Nature Reviews Drug Discovery, vol. 10, no 9, , p. 698–712 (ISSN1474-1784, DOI10.1038/nrd3505, lire en ligne, consulté le )
(en) Joseph W. Arndt, Fang Qian, Benjamin A. Smith et Chao Quan, « Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β », Scientific Reports, vol. 8, no 1, , p. 6412 (ISSN2045-2322, DOI10.1038/s41598-018-24501-0, lire en ligne, consulté le )
(en) Eric Karran, Marc Mercken et Bart De Strooper, « The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics », Nature Reviews Drug Discovery, vol. 10, no 9, , p. 698–712 (ISSN1474-1784, DOI10.1038/nrd3505, lire en ligne, consulté le )
(en) Toyn, « What lessons can be learned from failed Alzheimer's disease trials? », Expert Rev. Clin. Pharmacol, vol. 8, no 3, , p. 267-9. (PMID25860157, DOI10.1586/17512433.2015.1034690)
Sevigny J., Chiao P., Bussière T. et Weinreb P.H., « The antibody aducanumab reduces Aβ plaques in Alzheimer's disease », Nature, vol. 537, no 7618, , p. 50-6. (PMID27582220, DOI10.1038/nature19323)